Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/31/2026

1. NVDA
2. PCG
3. AVGO
4. CNS
5. ALNY
6. SRE
7. HDB
8. ATTO
9. BRVE
10. EIX

Go back to Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 218.24 -0.26 (0.12%)
Previous Close $218.50    52 Week High $333.65 
Open $216.47    52 Week Low $223.02 
Day High $218.89    P/E 27.94 
Day Low $213.58    EPS $7.81 
Volume 186,509       

(NASDAQ: BIIBV) Delayed: 259.61 --0 (-0%)
Previous Close $259.61    52 Week High $ 
Open $0.00    52 Week Low $ 
Day High $259.61    P/E N/A 
Day Low $259.61    EPS $ 
Volume 19,000       

Bristol-Myers Squibb (NYSE: BMY) Delayed: 66.55 -0.03 (0.05%)
Previous Close $66.58    52 Week High $77.12 
Open $66.25    52 Week Low $49.03 
Day High $66.71    P/E 43.21 
Day Low $65.91    EPS $1.54 
Volume 1,963,649